Pre-made Garetosmab benchmark antibody ( Whole mAb, anti-INHBA/ACT therapeutic antibody, Anti-EDF/FRP Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Garetosmab biosimilar, Whole mAb, Anti-INHBA/ACT Antibody: Anti-EDF/FRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Garetosmab is a VelocImmune-derived fully-human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. Garetosmab is currently being studied in adults with FOP.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-234-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Garetosmab biosimilar, Whole mAb, Anti-INHBA/ACT Antibody: Anti-EDF/FRP therapeutic antibody
INN Name	Garetosmab
Target	ACT
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Regeneron Pharmaceuticals
Conditions Approved	na
Conditions Active	Fibrodysplasia ossificans progressiva;Osteroporosis
Conditions Discontinued	Musculoskeletal disorders
Development Tech	na